Targeting of CAT and VCAM1 as Novel Therapeutic Targets for DMD Cardiomyopathy.

Front Cell Dev Biol · 2021 · PMC8047121 · PMID 33869226

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Compared to vehicle treatment, Kae, Que, VitC, and Dla treatment significantly decreased total ROS accumulation in DMD hiPSC-CMs while Dios, Nar, Oxl only showed a trend ( Figures 5A,B ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.